Drug names
Pro Research Analysisby 
Searched over 200M research papers for "drug names"
Drug Names: Challenges and Solutions in Medication Safety
Introduction to Drug Name Confusion
Drug name confusion is a significant issue in healthcare, leading to medication errors that can harm patients. Many drug names look or sound similar, which can cause confusion among healthcare providers and patients. This problem is particularly prevalent with brand (proprietary) names, such as Celebrex® (celecoxib), Cerebyx® (fosphenytoin), and Celexa® (citalopram)1. Factors like poor handwriting and clinical similarity exacerbate these issues, necessitating actions from regulatory agencies, pharmaceutical manufacturers, healthcare professionals, and patients to mitigate risks1.
The Complex Process of Naming Drugs
Chemical, Generic, and Brand Names
Every drug has three distinct names: the chemical name, the generic (nonproprietary) name, and the brand (proprietary) name. The chemical name specifies the drug's molecular structure and is primarily used by researchers. However, it is often long and difficult to pronounce, making it impractical for everyday use2. The generic name, created when a new drug is ready to be marketed, is essential for healthcare professionals as it provides information about the drug's chemical composition and pharmacologic action2. The brand name, chosen by the manufacturer for marketing purposes, must be approved by the FDA and is designed to be memorable and distinct2.
Naming Guidelines and Approval Process
The United States Adopted Names (USAN) Council, in conjunction with the World Health Organization (WHO), oversees the approval of generic names. The process ensures that names are not too similar to existing ones and are appropriate for the drug2. The USAN Council follows strict guidelines to create names that are short, easy to pronounce, and useful for healthcare providers2. Brand names, while more flexible, must also avoid excessive similarity to existing names to prevent confusion2.
Designing Safe Drug Names
Preapproval Testing and Strategies
Designing safe drug names involves multiple-objective optimization, balancing technical, legal, and safety constraints. Preapproval tests include computerized searches for similar names, expert judgments, psycholinguistic tests, and simulated tasks to observe error rates4. Strategies to prevent confusion between similar names include collecting voluntary reports of errors, posting warnings, and using distinct storage and labeling practices4.
Regulatory and Manufacturer Roles
Regulatory authorities and manufacturers play crucial roles in ensuring drug names are distinct and safe. Licensing authorities should exercise more control over naming, and manufacturers should choose names carefully and consider internationalization5. Healthcare professionals are encouraged to use both generic and brand names when prescribing to reduce errors5.
Real-World Implications and Case Studies
Confusion over similar drug names has led to serious medication errors. For instance, Durasal (salicylic acid) was mistakenly dispensed instead of Durezol (difluprednate), causing patient harm7. Similar issues have been reported with drugs like Pradax (dabigatran) and Plavix (clopidogrel)7. These cases highlight the importance of thorough premarket testing and vigilant postmarket monitoring to prevent such errors7.
Conclusion
Drug name confusion is a persistent challenge in healthcare, but it can be mitigated through careful naming practices, rigorous testing, and collaboration among regulatory bodies, manufacturers, and healthcare professionals. By adhering to established guidelines and continuously monitoring for potential errors, the goal of minimizing medication errors and enhancing patient safety can be achieved.
Sources and full results
Most relevant research papers on this topic
Medication Errors Caused by Confusion of Drug Names
Confusion of drug names can lead to medication errors, which can be alleviated through regulatory agencies, pharmaceutical manufacturers, healthcare professionals, and patients.
Highly Cited